Agarwal Shares Insight on Promise With Cabozantinib/Atezolizumab in mCRPC

Kristi Rosa
Published: Tuesday, Feb 25, 2020
Neeraj Agarwal, MD, associate professor of medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute

Neeraj Agarwal, MD

The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) demonstrated exciting clinical activity and a tolerable safety profile in patients with metastatic castration-resistant prostate cancer (mCRPC) in cohort 6 of the phase Ib COSMIC-021 trial (NCT03170960), according to Neeraj Agarwal, MD, adding that a phase III trial is planned to explore the combination in a larger group of patients.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x